First Tracks Biotherapeutics Reports Positive Phase 1b ANB033 Results
The company said ANB033 showed statistically significant protection against gluten-induced intestinal damage and symptoms.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
First Tracks Biotherapeutics Reports Positive Phase 1b Celiac Data
The company reported statistically significant histology and symptom benefits for ANB033 versus placebo in a 14-day gluten challenge, with no serious adverse events and a favorable safety profile.
Stock Market Today: S&P 500, Dow Jones Futures Gain Even as Iran Flags 'Inadequate' US Response to Peace Terms — SMP, QMCO, SVRN in Focus
U.S. stock futures were mixed on Monday, as the Dow Jones and S&P 500 indices rose, while the Nasdaq 100 index fell, following Friday’s higher close. Geopolitical tensions flared over the weekend as Iran stepped up attacks on shipping near the Strait of Hormuz and threatened regional digital infrastructure, citing an “